Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Fatty Liver Alliance: Advancing Awareness and Advocacy for MASLD and MASH
Steatotic Liver Disease (MASLD/MASH)

Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Signed in as:
filler@godaddy.com
Steatotic Liver Disease (MASLD/MASH)
The Fatty Liver Alliance invites you to take part in our 3rd Annual 30 Day Glucose Challenge, starting July 1!
This challenge is a powerful opportunity to raise awareness and take action around Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic dysfunction-Associated Steatohepatitis (MASH), two of the most common and underdiagnosed liver conditions linked to insulin resistance and glucose spikes.
By using a Continuous Glucose Monitor (CGM) for 10, 15, 20, or 30 days, you'll learn in real time how food, activity, stress, and sleep affect your glucose levels, and by extension, your liver health.
What if the first step in treating liver disease isn’t a test, a medication, or even a diagnosis, but how we speak?
That was the heart of the opening keynote at the Your Health Matters Summit. where Dr. Sean Wharton and Dr. Gillian Mandich challenged us to rethink how we approach people living with obesity and chronic conditions like MASLD and MASH, and it’s exactly what the People-First Liver Charter, published in Nature Medicine, is all about.
The projections from the JAMA Network Open study represent a business-as-usual trajectory—a status quo where awareness remains low, screening rates are modest, and treatment access remains limited. But the world is already changing:
With these trends in motion, the real future of MASLD may diverge from the grim path laid out in the modeling study.
We’re in an era where metabolic dysfunction-associated steatohepatitis (MASH) affects millions globally, and treatment options are still evolving. But one thing remains constant: lifestyle modification is the foundation of care. Professor Zelber-Sagi emphasized that weight loss, dietary changes, and physical activity have the most robust evidence in reversing disease progression..
Dr. Abdelmalek emphasized that no matter how promising the pharmacologic pipeline becomes, lifestyle modification remains central. However, real-world limitations—challenges with long-term adherence, comorbidities, and systemic barriers—mean that medication is a necessary complement for many.
The statistics are clear—MASLD is on the rise, and without urgent intervention, its impact will only worsen. Addressing this crisis requires more than just awareness; it demands a fundamental shift in how we educate future physicians.
Nonalcoholic steatohepatitis (NASH), now classified under metabolic dysfunction-associated steatohepatitis (MASH), is a progressive liver disease that can lead to fibrosis, cirrhosis, and severe liver complications. The challenge in managing MASH has always been how to effectively monitor patient response to treatment without relying on invasive liver biopsies.
At the recent Desert Liver Conference, Dr. Mazen Noureddin provided valuable insights into non-invasive methods for tracking treatment response, discussing both clinical trial applications and real-world practice.
Summary of Dr. Naim Alkhouri’s Presentation on Non-Invasive Tests (NITs) for MASLD/MASH Screening in Clinical Practice from the Desert Liver Conference 2025.
Dr. Naim Alkhouri, along with Dr. Mazen Noureddin and Dr. Meena Bansal (summaries of their presentations to follow), discussed the clinical perspective on non-invasive tests (NITs) for identifying and managing MASLD/MASH patients, particularly in primary care and diabetes clinics.
The Fatty Liver Alliance a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian regulators for approval of Rezdiffra (resmetirom), the company’s oral therapy for metabolic dysfunction-associated steatohepatitis (MASH).
https://liverdiseasenews.com/news/nonprofits-petition-aims-expedite-canadian-access-rezdiffra/
Today, we're taking a crucial step forward in advocating for Canadians diagnosed with MASH (Metabolic dysfunction-Associated Steatohepatitis).
We've launched a petition asking Madrigal Pharmaceuticals to apply to Health Canada, so that Canadians can have access to Rezdiffra—a vital treatment for MASH.
Your support is essential! Please take a moment to sign our petition and share this with your network. Together, we can make a difference!
🔗 Sign the Petition Here: https://globalliver.salsalabs.org/petitionrezdiffracanada
🔗 Read Our Media Release: Urgent Call to Action: Canadians Deserve Equal Access to Life-Saving Liver Treatment--Sign the Petition Now!
Thank you for standing with us in this important cause.
Our amazing team of full and part-time volunteers are committed to helping others. We take our convictions and turn them into action. Think you would be a good fit? Get in touch for more information!
Our nonprofit charity was created to build a supportive community. Canada’s population is about 38.8M with an estimated 15.5M who may have Metabolic Dysfunction Associated Liver Disease (MASLD) (formerly NAFLD). Of those, an estimated 20% - 25% will progress to cirrhosis and suffer with Metabolic-dysfunction Associated Steatohepatitis (MASH) (formerly NASH).
We raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with MASLD or MASH by advocating for access to approved treatments and care.
Your support and contributions will enable our Registered Charity to meet our goals and your generous donations will fund our mission and purpose. Charity #79690 4704 RR0001
We will issue a tax receipt for donations of $18.00 or greater.
**Best option for us, is e-transfer to donations@fattyliver.ca
In the comment section, we need your full name and address so we can issue a tax receipt. Other payment options below.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.